NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage antiviral drug developer, has highlighted the potential of its broad-spectrum antiviral candidate NV-387 in response to the ongoing Bundibugyo Ebola outbreak in the Democratic Republic of Congo and Uganda. The company stated that NV-387, an oral drug candidate, could offer a differentiated approach if proven effective against the virus strain, positioning it as a tool for pandemic preparedness against Ebola and related viral threats.
The company emphasized NV-387's proposed mechanism targeting viral cell attachment pathways common across filoviruses, the family that includes Ebola and Marburg viruses. This mechanism could make NV-387 effective against multiple viral strains, including the Bundibugyo species responsible for the current outbreak. According to the press release, NanoViricides holds a worldwide exclusive perpetual license for Ebola/Marburg viruses as part of its platform technology based on TheraCour nanomedicine.
NV-387 is the lead drug candidate for NanoViricides, initially developed as a broad-spectrum antiviral for respiratory infections such as RSV, COVID-19, influenza, and others, including MPOX and measles. The company is currently focused on advancing NV-387 into Phase II human clinical trials. The candidate is also being explored for use against other viral diseases, such as oral and genital herpes, viral eye infections, HIV, hepatitis C, rabies, dengue, and Ebola.
The announcement comes as the World Health Organization reports ongoing transmission of the Bundibugyo Ebola virus in Uganda and the Democratic Republic of Congo. While there are approved vaccines and treatments for the Zaire strain of Ebola, the Bundibugyo strain has no specific approved therapies, highlighting the need for broad-spectrum antivirals.
NanoViricides' technology involves special purpose nanomaterials designed to mimic host cell receptors, thereby binding to viruses and neutralizing them. The company's drug candidate NV-CoV-2 (API NV-387) is a nanoviricide for COVID-19 that does not encapsulate remdesivir, while NV-CoV-2-R encapsulates remdesivir within polymeric micelles. The company believes that since remdesivir is already FDA-approved, the encapsulated version could be approvable if safety is comparable. Remdesivir is developed by Gilead.
The company noted that the path to typical drug development is extremely lengthy and requires substantial capital, and there can be no assurance that any of its candidates will show sufficient effectiveness and safety for human clinical development. The press release also reminded investors that successful lab results do not guarantee successful clinical trials or a commercial product.
For more information on NanoViricides and its pipeline, visit the company's newsroom at https://ibn.fm/NNVC. The full press release is available at https://ibn.fm/mm3Z5.
